In fact, an albumin–paclitaxel nanoparticle (Abraxane®), which has been approved for the treatment of breast, lung, pancreatic, and small cell lung cancers worldwide, was designed and developed using albumin to both increase the water solubility of paclitaxel (innate biological characteristic of albumin) and control the size of particles to permit them to accumulate in the solid tumor (carrier) [1,2]. This evidence concerns the gene ALB and small cell lung carcinoma.